Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 254

1.

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA.

Antiviral Res. 2006 Jun;70(2):28-38. Epub 2006 Jan 13.

PMID:
16448708
[PubMed - indexed for MEDLINE]
2.

A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.

Chase R, Skelton A, Xia E, Curry S, Liu S, McMonagle P, Huang HC, Tong X.

Antiviral Res. 2009 Nov;84(2):178-84. doi: 10.1016/j.antiviral.2009.09.003. Epub 2009 Sep 10.

PMID:
19747948
[PubMed - indexed for MEDLINE]
3.

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

Lin C, Gates CA, Rao BG, Brennan DL, Fulghum JR, Luong YP, Frantz JD, Lin K, Ma S, Wei YY, Perni RB, Kwong AD.

J Biol Chem. 2005 Nov 4;280(44):36784-91. Epub 2005 Aug 8.

PMID:
16087668
[PubMed - indexed for MEDLINE]
Free Article
4.

Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations.

Yi M, Tong X, Skelton A, Chase R, Chen T, Prongay A, Bogen SL, Saksena AK, Njoroge FG, Veselenak RL, Pyles RB, Bourne N, Malcolm BA, Lemon SM.

J Biol Chem. 2006 Mar 24;281(12):8205-15. Epub 2005 Dec 13.

PMID:
16352601
[PubMed - indexed for MEDLINE]
Free Article
5.

Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.

Tong X, Arasappan A, Bennett F, Chase R, Feld B, Guo Z, Hart A, Madison V, Malcolm B, Pichardo J, Prongay A, Ralston R, Skelton A, Xia E, Zhang R, Njoroge FG.

Antimicrob Agents Chemother. 2010 Jun;54(6):2365-70. doi: 10.1128/AAC.00135-10. Epub 2010 Mar 22.

PMID:
20308381
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.

Courcambeck J, Bouzidi M, Perbost R, Jouirou B, Amrani N, Cacoub P, Pèpe G, Sabatier JM, Halfon P.

Antivir Ther. 2006;11(7):847-55.

PMID:
17302247
[PubMed - indexed for MEDLINE]
7.

Characterization of resistance mutations against HCV ketoamide protease inhibitors.

Tong X, Bogen S, Chase R, Girijavallabhan V, Guo Z, Njoroge FG, Prongay A, Saksena A, Skelton A, Xia E, Ralston R.

Antiviral Res. 2008 Mar;77(3):177-85. doi: 10.1016/j.antiviral.2007.11.010. Epub 2007 Dec 28.

PMID:
18201776
[PubMed - indexed for MEDLINE]
8.

Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).

Flint M, Mullen S, Deatly AM, Chen W, Miller LZ, Ralston R, Broom C, Emini EA, Howe AY.

Antimicrob Agents Chemother. 2009 Feb;53(2):401-11. doi: 10.1128/AAC.01081-08. Epub 2008 Oct 20.

PMID:
18936191
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.

Dahl G, Sandström A, Akerblom E, Danielson UH.

Antivir Ther. 2007;12(5):733-40.

PMID:
17713156
[PubMed - indexed for MEDLINE]
10.

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms.

Lin C, Lin K, Luong YP, Rao BG, Wei YY, Brennan DL, Fulghum JR, Hsiao HM, Ma S, Maxwell JP, Cottrell KM, Perni RB, Gates CA, Kwong AD.

J Biol Chem. 2004 Apr 23;279(17):17508-14. Epub 2004 Feb 6.

PMID:
14766754
[PubMed - indexed for MEDLINE]
Free Article
11.

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.

Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, Hughes E, Ralston R, Tong X, Herrmann E, Zeuzem S, Sarrazin C.

Hepatology. 2009 Dec;50(6):1709-18. doi: 10.1002/hep.23192.

PMID:
19787809
[PubMed - indexed for MEDLINE]
12.

Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.

He Y, King MS, Kempf DJ, Lu L, Lim HB, Krishnan P, Kati W, Middleton T, Molla A.

Antimicrob Agents Chemother. 2008 Mar;52(3):1101-10. Epub 2007 Dec 17.

PMID:
18086851
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.

Lu L, Pilot-Matias TJ, Stewart KD, Randolph JT, Pithawalla R, He W, Huang PP, Klein LL, Mo H, Molla A.

Antimicrob Agents Chemother. 2004 Jun;48(6):2260-6.

PMID:
15155230
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors.

Yang W, Zhao Y, Fabrycki J, Hou X, Nie X, Sanchez A, Phadke A, Deshpande M, Agarwal A, Huang M.

Antimicrob Agents Chemother. 2008 Jun;52(6):2043-52. doi: 10.1128/AAC.01548-07. Epub 2008 Apr 14.

PMID:
18411324
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.

Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Müh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD.

Gastroenterology. 2007 May;132(5):1767-77. Epub 2007 Feb 21.

PMID:
17484874
[PubMed - indexed for MEDLINE]
16.

Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.

López-Labrador FX, Moya A, Gonzàlez-Candelas F.

Antivir Ther. 2008;13(4):481-94.

PMID:
18672527
[PubMed - indexed for MEDLINE]
17.

HCV-NS3 inhibitors: determination of their kinetic parameters and mechanism.

Flores MV, Strawbridge J, Ciaramella G, Corbau R.

Biochim Biophys Acta. 2009 Oct;1794(10):1441-8. doi: 10.1016/j.bbapap.2009.06.004. Epub 2009 Jun 6.

PMID:
19505593
[PubMed - indexed for MEDLINE]
Free Article
18.

SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.

Malcolm BA, Liu R, Lahser F, Agrawal S, Belanger B, Butkiewicz N, Chase R, Gheyas F, Hart A, Hesk D, Ingravallo P, Jiang C, Kong R, Lu J, Pichardo J, Prongay A, Skelton A, Tong X, Venkatraman S, Xia E, Girijavallabhan V, Njoroge FG.

Antimicrob Agents Chemother. 2006 Mar;50(3):1013-20.

PMID:
16495264
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase.

Kukolj G, McGibbon GA, McKercher G, Marquis M, Lefèbvre S, Thauvette L, Gauthier J, Goulet S, Poupart MA, Beaulieu PL.

J Biol Chem. 2005 Nov 25;280(47):39260-7. Epub 2005 Sep 27.

PMID:
16188890
[PubMed - indexed for MEDLINE]
Free Article
20.

Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.

Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, Tigges AM, Adiwijaya BS, Lin C, Kwong AD, Kieffer TL.

J Infect Dis. 2008 Sep 15;198(6):800-7. doi: 10.1086/591141.

PMID:
18637752
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk